CN108101915A - 一类聚胺衍生化的开环葫芦脲及应用 - Google Patents
一类聚胺衍生化的开环葫芦脲及应用 Download PDFInfo
- Publication number
- CN108101915A CN108101915A CN201711129501.XA CN201711129501A CN108101915A CN 108101915 A CN108101915 A CN 108101915A CN 201711129501 A CN201711129501 A CN 201711129501A CN 108101915 A CN108101915 A CN 108101915A
- Authority
- CN
- China
- Prior art keywords
- open loop
- derivatization
- polyamine
- loop cucurbituril
- cucurbituril
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MSBXTPRURXJCPF-DQWIULQBSA-N cucurbit[6]uril Chemical compound N1([C@@H]2[C@@H]3N(C1=O)CN1[C@@H]4[C@@H]5N(C1=O)CN1[C@@H]6[C@@H]7N(C1=O)CN1[C@@H]8[C@@H]9N(C1=O)CN([C@H]1N(C%10=O)CN9C(=O)N8CN7C(=O)N6CN5C(=O)N4CN3C(=O)N2C2)C3=O)CN4C(=O)N5[C@@H]6[C@H]4N2C(=O)N6CN%10[C@H]1N3C5 MSBXTPRURXJCPF-DQWIULQBSA-N 0.000 title claims abstract description 57
- 238000001212 derivatisation Methods 0.000 title claims abstract description 45
- 229920000768 polyamine Polymers 0.000 title claims abstract description 25
- 239000003937 drug carrier Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 abstract description 26
- 229940079593 drug Drugs 0.000 abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 9
- 125000003368 amide group Chemical group 0.000 abstract description 3
- 229920000642 polymer Polymers 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 17
- 238000005481 NMR spectroscopy Methods 0.000 description 13
- 125000001246 bromo group Chemical group Br* 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 12
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 229960001124 trientine Drugs 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 4
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 4
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229930014456 matrine Natural products 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229930015582 oxymatrine Natural products 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FAGUFWYHJQFNRV-UHFFFAOYSA-N tetraethylenepentamine Chemical compound NCCNCCNCCNCCN FAGUFWYHJQFNRV-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 240000009087 Crescentia cujete Species 0.000 description 1
- 235000005983 Crescentia cujete Nutrition 0.000 description 1
- 235000009797 Lagenaria vulgaris Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- HINSMVRGSUGPBM-UHFFFAOYSA-N acetyl 2,2,2-trifluoroacetate Chemical compound CC(=O)OC(=O)C(F)(F)F HINSMVRGSUGPBM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 229960004991 artesunate Drugs 0.000 description 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- VTJUKNSKBAOEHE-UHFFFAOYSA-N calixarene Chemical class COC(=O)COC1=C(CC=2C(=C(CC=3C(=C(C4)C=C(C=3)C(C)(C)C)OCC(=O)OC)C=C(C=2)C(C)(C)C)OCC(=O)OC)C=C(C(C)(C)C)C=C1CC1=C(OCC(=O)OC)C4=CC(C(C)(C)C)=C1 VTJUKNSKBAOEHE-UHFFFAOYSA-N 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000003916 ethylene diamine group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- VPVSTMAPERLKKM-UHFFFAOYSA-N glycoluril Chemical compound N1C(=O)NC2NC(=O)NC21 VPVSTMAPERLKKM-UHFFFAOYSA-N 0.000 description 1
- 125000001046 glycoluril group Chemical group [H]C12N(*)C(=O)N(*)C1([H])N(*)C(=O)N2* 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一类聚胺衍生化的开环葫芦脲,其结构通式如下:
Description
技术领域
本发明属于药用超分子药物载体的制备领域,具体涉及一种聚胺衍生化的开环葫芦脲。
背景技术
超分子化学是一门多学交叉形成的新型学科,主要涵盖化学、材料学、药学及生物学等热点研究领域;其中超分子药物载体的构筑隶属于超分子化学领域,超分子药物载体一般具有疏水性空腔,能把尺寸合适的药物封装在空腔内部,能够增加药物的水溶性、稳定性。现在比较热门的超分子药物载体主要包括环糊精、杯芳烃、柱芳烃、冠醚、葫芦脲等;
葫芦脲是近些年来发展比较迅速的超分子药物载体,由甘脲和多聚甲醛在强酸的条件制备而成的,根据甘脲单元的个数分为CB[5]、CB[6]、CB[7]、CB[8]、CB[10],其中CB[7]由于具有较强的水溶性,常常被用于超分子药物载体,增加药物的水溶性,运输药物分子。
开环葫芦脲与闭环葫芦脲相比,在结构上由原来的环状结构变成了开环结构,容易被其他基团修饰,也可以被功能化制备成不同用途的的超分子药物载体,比如靶向载体、基因载体等等。在物理性质上面,能使药物包合在空腔内并且Ks值适中,当到达作用部位时,又能使药物从空腔脱离,起到很好的作用。
类比于开环葫芦脲,专利CN104016994提出了一种闭环葫芦脲衍生化的制备方法。对环糊精的多聚胺基修饰之前也有一些文献进行报道(具体制备方法参见Bao-Jian Shen,Lin-Hui Tong, Dao-Sen Jin. Synthetic Communications, 1991, 21(5):635-641.)。对开环葫芦脲的衍生化也有类似的文献报道(1.Zhang B, Zavalij P Y, Isaacs L.Organic & Biomolecular Chemistry, 2014, 12(15):2413-22. 2.Zhang M, Sigwalt D,Isaacs L. Chemical Communications, 2015, 51(78):14620-3.),但对于开环葫芦脲的多聚胺基修饰却未见报道。
苦参碱、氧化苦参碱都具有较好的抗肿瘤活性,但是它们都具有较差的水溶性,这在某种程度上限制了它们直接成药;采用聚胺衍生化的开环葫芦脲对这些药物进行包合未见报道。
发明内容
本发明目的是提供一种水溶性极佳、稳定性极佳、没有毒副作用的聚胺衍生化的开环葫芦脲;该聚胺衍生化的开环葫芦脲是以溴代开环葫芦脲和水溶性较好的聚胺类物质为原料,将聚胺与开环葫芦脲进行键接,制备得到了药用超分子载体。
本发明聚胺衍生化开环葫芦脲的结构通式如下:
,其中n为0、1、2或3。
所述聚胺衍生化的开环葫芦脲四个臂的n值保持一致,即该类聚胺衍生化的开环葫芦脲为完全对称型结构。
本发明聚胺衍生化开环葫芦脲聚合物是一种水溶性极好的药物载体,它利用开环葫芦脲疏水性空腔腔可与一些空间匹配的药物形成包合物,从而对这种被包合的药物进行改性,提高药物的稳定性以及水溶性。现在市面上有许多活性化合物具有不错的疗效,但是由于本身水溶性或稳定性欠佳的原因,很难单独成药,例如抗癌药物阿霉素、青蒿琥酯、双氢青篙素、苦参碱以及氧化苦参碱。
本发明另一目的是将聚胺衍生化的开环葫芦脲应用在作为药物载体中,例如作为生物碱药物的载体,能够增加难溶性生物碱药物的水溶性,提高其生物利用度。
本发明聚合物具体制备过程如下:
(1)称取一定量预先制备的溴代开环葫芦脲(制备方法参见Zhang B,Zavalij P Y,Isaacs L. Organic & Biomolecular Chemistry,2014,12(15):2413-2422中方法),加入到聚胺溶液中,以聚胺为溶剂,在80℃加热条件下反应24h(整个反应过程要在氮气保护的条件下进行);
(2)反应后的混合液缓慢滴加到丙酮溶液中除去未完全反应的聚胺类化合物,得到的沉淀即为聚胺衍生化的开环葫芦脲粗产物,粗产物在丙酮溶液中重结晶(反沉淀)3-4次除去溴代开环葫芦脲后干燥即得纯的聚胺衍生化开环葫芦脲。
所述聚胺为乙二胺、二乙烯三胺、三乙烯四胺、四乙烯五胺等,当n=0时,为乙二胺衍生化开环葫芦脲;当n=1时,为二乙烯三胺衍生化开环葫芦脲;当n=2时,为三乙烯四胺衍生化开环葫芦脲;当n=3时,为四乙烯五胺衍生化开环葫芦脲。
本发明反应的过程如下:
其中n为0、1、2或3。
本发明的优点和效果如下:
本发明提供的超分子药物载体聚胺衍生化的开环葫芦脲,与药物分子有适当的Ks值,有望作为一种水溶性极佳、稳定性极佳、没有毒副作用的超分子药物载体;另一方面,本发明所述的超分子药物载体聚胺化衍生的开环葫芦脲的制备方法,操作简单,反应条件温和,所得产品收率高,纯度高,可用于工业化生产。
附图说明
图1是溴代开环葫芦脲的核磁共振氢谱(1H NMR)图;
图2是乙二胺衍生化开环葫芦脲的核磁共振氢谱(1H NMR)图;
图3是二乙烯三胺衍生化开环葫芦脲的核磁共振氢谱(1H NMR)图;
图4是三乙烯四胺衍生化开环葫芦脲的核磁共振氢谱(1H NMR)图。
图5是乙二胺衍生化开环葫芦脲-苦参碱包合物的核磁共振氢谱(1H NMR)图;
图6是乙二胺衍生化开环葫芦脲-氧化苦参碱包合物的核磁共振氢谱(1H NMR)图。
具体实施方式
下面通过实施例对本发明作进一步详细说明,但本发明保护范围不局限于所述内容。
实施例1:溴代开环葫芦脲的制备
取四聚体(制备方法参见Ma D,Hettiarachchi G,Nguyen D,et al. Nature Chemistry, 2012,4(6):503中方法)3g、1,4-二(2-溴乙氧基)苯6g加入50mL圆底烧瓶中,然后加入到体积比为1:1的三氟乙酸-乙酸酐混合溶液中,在70℃条件下反应3h,调节pH至中性后,用甲醇和丙酮进行重结晶,得到溴代开环葫芦脲2.513g,产率为35.2%,溴代开环葫芦脲的核磁共振氢谱(1H NMR)如图1所示。
实施例2:称取实施例1制备的溴代开环葫芦脲1.38g,加入到10 mL乙二胺溶液中,以乙二胺为溶剂,在80℃加热条件下反应24h(整个反应过程要在氮气保护的条件下进行);反应后的混合液缓慢滴加到200 mL丙酮溶液中除去未完全反应的乙二胺,得到的沉淀即为乙二胺生化开环葫芦脲粗产物,粗产物用50 mL丙酮重结晶(反沉淀)3次除去溴代开环葫芦脲后干燥得纯的乙二胺衍生化开环葫芦脲0.85g,产率为65.2%,乙二胺衍生化开环葫芦脲的核磁共振氢谱(1H NMR)如图2所示;
,其中n为0。
实施例3:称取实施例1制备的溴代开环葫芦脲1.38g,加入到15 mL二乙烯三胺溶液中,以二乙烯三胺为溶剂,在80℃加热条件下反应24h(整个反应过程要在氮气保护的条件下进行)。反应后的混合液缓慢滴加到250 mL丙酮溶液中除去未完全反应的二乙烯三胺,得到的沉淀即为二乙烯三胺衍生化开环葫芦脲粗产物,粗产物用80 mL丙酮重结晶(反沉淀)4次除去溴代开环葫芦脲后干燥得纯的二乙烯三胺衍生化开环葫芦脲0.715g,产率为58.6%(二乙烯三胺衍生化开环葫芦脲的核磁共振氢谱(1H NMR)如图3所示);
,其中n为1。
实施例4:称取实施例1制备的溴代开环葫芦脲1.38g,加入到15 mL三乙烯四胺溶液中,以三乙烯四胺为溶剂,在80℃加热条件下反应24h(整个反应过程要在氮气保护的条件下进行)。反应后的混合液缓慢滴加到250 mL丙酮溶液中除去未完全反应的三乙烯四胺,得到的沉淀即为三乙烯四胺衍生化开环葫芦脲粗产物,粗产物用80 mL丙酮重结晶(反沉淀)3次除去溴代开环葫芦脲后干燥得纯的三乙烯四胺衍生化开环葫芦脲0.647g,产率为51.2%(三乙烯四胺衍生化开环葫芦脲的核磁共振氢谱(1H NMR)如图4所示);
,其中n为2。
实施例5:乙二胺衍生化的开环葫芦脲-苦参碱包合物的制备
分别称取乙二胺衍生化的开环葫芦脲0.1308g(0.1mmol)和苦参碱0.0248g(0.1mmol),加入到3mL重水中,在室温的条件下,避光搅拌4天;用微孔滤膜除去不溶物,滤液装样,使用核磁共振氢谱仪对包合物的形成进行鉴定,乙二胺衍生化开环葫芦脲-苦参碱包合物的核磁共振氢谱(1H NMR)如图5所示;所选用的模型药物不溶于重水,不会出现氢质子的峰;但是形成的包合物能够增加模板药物在重水中的溶解度,会出现模板药物氢质子的峰。
实施例6:乙二胺衍生化的开环葫芦脲-氧化苦参碱包合物的制备
分别称取乙二胺衍生化开环葫芦脲0.1308g(0.1mmol)和氧化苦参碱0.0264g(0.1mmol),加入到3mL重水中,在室温的条件下,避光搅拌4天;用微孔滤膜除去不溶物,滤液装样,使用核磁共振氢谱仪对包合物的形成进行鉴定,乙二胺衍生化开环葫芦脲-氧化苦参碱包合物的核磁共振氢谱(1H NMR)如图6所示,所选用的模型药物不溶于重水,不会出现氢质子的峰;但是形成的包合物能够增加模板药物在重水中的溶解度,会出现模板药物氢质子的峰。
实施例7:向1mL水中加入过量的乙二胺开环葫芦脲-模板药物包合物,制备其饱和水溶液,微孔滤膜过滤除去过量的包合物,滤液用旋转蒸发仪旋干,称重,与模板药物水溶性对比结果见表1、表2;
表1 苦参碱及两种包合物水溶性试验数据表
表2 氧化苦参碱及两种包合物水溶性试验数据表
。
Claims (2)
1.一类聚胺衍生化的开环葫芦脲,其结构通式如下:
,其中n为0、1 、2或3。
2.权利要求1所述的聚胺衍生化的开环葫芦脲在作为药物载体中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711129501.XA CN108101915B (zh) | 2017-11-15 | 2017-11-15 | 一类聚胺衍生化的开环葫芦脲及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711129501.XA CN108101915B (zh) | 2017-11-15 | 2017-11-15 | 一类聚胺衍生化的开环葫芦脲及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108101915A true CN108101915A (zh) | 2018-06-01 |
CN108101915B CN108101915B (zh) | 2020-07-10 |
Family
ID=62206553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711129501.XA Active CN108101915B (zh) | 2017-11-15 | 2017-11-15 | 一类聚胺衍生化的开环葫芦脲及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108101915B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108771675A (zh) * | 2018-07-19 | 2018-11-09 | 昆明理工大学 | 青蒿素类药物与开环葫芦脲的包合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012051407A2 (en) * | 2010-10-13 | 2012-04-19 | University Of Maryland, College Park | Molecular containers and methods of making and using same |
WO2016061571A1 (en) * | 2014-10-18 | 2016-04-21 | University Of Maryland, College Park | Acyclic cucurbit(n)uril type molecular containers to treat intoxication and decrease relapse rate in substance abuse disorders |
-
2017
- 2017-11-15 CN CN201711129501.XA patent/CN108101915B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012051407A2 (en) * | 2010-10-13 | 2012-04-19 | University Of Maryland, College Park | Molecular containers and methods of making and using same |
WO2016061571A1 (en) * | 2014-10-18 | 2016-04-21 | University Of Maryland, College Park | Acyclic cucurbit(n)uril type molecular containers to treat intoxication and decrease relapse rate in substance abuse disorders |
Non-Patent Citations (2)
Title |
---|
BEN ZHANG 等: "Acyclic CB[n]-type molecular containers: effect of solubilizing group on their function as solubilizing excipients", 《ORG. BIOMOL. CHEM》 * |
DA MA 等: "Acyclic Cucurbit[n]uril Congeners Are High Affinity Hosts", 《J. ORG. CHEM.》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108771675A (zh) * | 2018-07-19 | 2018-11-09 | 昆明理工大学 | 青蒿素类药物与开环葫芦脲的包合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN108101915B (zh) | 2020-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shuang et al. | Preparation of a stilbene diamido-bridged bis (β-cyclodextrin)-bonded chiral stationary phase for enantioseparations of drugs and pesticides by high performance liquid chromatography | |
CN103497154A (zh) | 一种水溶性苝酰亚胺类化合物及其作为dna嵌插剂和在抑制癌细胞生长中的应用 | |
CN105017798B (zh) | 一种水不溶性天然黑色素的提取方法 | |
CN107245028B (zh) | 联苯芳烃、水溶性联苯芳烃及其制备方法 | |
CN106117253A (zh) | 一种瓜环与氨基酸合成的超分子配合物及制备方法和应用 | |
Chao et al. | Covalently bridged pillararene-based oligomers: from construction to applications | |
CN108101915A (zh) | 一类聚胺衍生化的开环葫芦脲及应用 | |
CN103435639A (zh) | 一种轴向核苷不对称修饰的硅酞菁及其制备方法和应用 | |
CN109675053A (zh) | 鬼臼毒素及其衍生物的靶向制剂及其制备方法 | |
CN103833623A (zh) | 一种氨基酸-胺缀合物及其制备方法和应用 | |
CN112125985B (zh) | 一类开环葫芦脲环糊精双主体化合物及其制备方法 | |
CN105153148A (zh) | 一种色胺酮生物碱盐及其制备方法和应用 | |
CN108003198B (zh) | 一种d-半乳糖键接的开环葫芦脲及应用 | |
CN109320552B (zh) | 具有良好生物活性的葛根素衍生物及其制备方法以及应用 | |
CN102924429A (zh) | 一种1,2-萘醌衍生物及其制备方法 | |
CN102775415B (zh) | 一种卟啉的合成方法 | |
CN101983189A (zh) | 异吲哚类的制造方法以及利用异吲哚类的制造方法制造的异吲哚类 | |
CN113620964A (zh) | 取代的杯咔唑衍生物及其合成方法和应用 | |
CN106632281B (zh) | 香豆素衍生物及其制备方法和应用 | |
CN109824541B (zh) | (1z,2z)-1,2-双((2-氟苯基)(4-氟苯基)亚甲基)肼的制备和用途 | |
CN103880848A (zh) | 一种双加成富勒烯吡咯烷及其制备方法 | |
Dai et al. | Two Propanediurea-based Cucurbituril Analogues: Bis-ns-TD [8] and NH-ns-TD [4] | |
CN108383765A (zh) | 苯丁酸氮芥-多巴胺缀合物的合成及前药纳米粒子的制备 | |
CN108264508A (zh) | 一种高纯度药用级罗通定原料的生产方法 | |
CN114478555B (zh) | 取代的杯[4]咔唑衍生物及其合成方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |